Naour, M. | Search bioRxiv

bioRxiv2026

Grey mouse lemurs, Microcebus murinus, are a relevant model to study gut microbiome flexibility in response to diet changes

The gut microbiota is a key player in energy balance, impacting both digestion efficiency and the production of metabolites involved in metabolism. Its composition is highly adaptable, especially in response to diet. Changes in human diet and lifestyle over time - from active, fibre-rich diets to sedentary habits with calorie-dense foods - have likely contributed to the rise in metabolic diseases. Rodent models are widely used to study the links between diet, microbiota and metabolism. However, they have important limitations (e.g. artificial environments, uniform diets and biological differences from humans) which can affect the translation of findings to humans. While mice and humans differ in their microbiota species, they do share some functional similarities. The grey mouse lemur (Microcebus murinus) has been proposed as a promising alternative model. This small primate experiences strong seasonal changes in food availability, leading to distinct physiological states (energy-saving in winter vs active in summer), even in captivity. It is increasingly recognized as a valuable model for biomedical research, supported by recent genomic and molecular advances. However, its gut microbiota has not yet been the subject of study. Consequently, the present study focuses on investigating the gut microbiota of the grey mouse lemur, with a particular emphasis on how these microbiota vary under different dietary regimens. The microbiota of animals fed the standard colony diet was dominated by Prevotella, Bifidobacterium, Megamonas, Streptococcus, Megasphaera and Lactococcus, showing an Prevotella driven enterosignature. We showed that switch from a classical control diet to 3 different diets resulted in change on microbiota composition that is associated with functional redundancy. The present work underline the interest of Microcebus murinus as model for diet and lifestyle studies in relationship with metabolic diseases.

microbiology↗

bioRxiv2025

MCL-1 as a molecular switch between myofibroblastic and pro-angiogenic features of breast cancer-associated fibroblasts

Breast cancer-associated fibroblasts (bCAFs) comprise inflammatory CAFs (iCAFs), characterized by the secretion of pro-inflammatory cytokines, and myofibroblastic CAFs (myCAFs), distinguished by their high production of extracellular matrix and their immunosuppressive properties. We previously showed that targeting the anti-apoptotic protein MCL-1 in primary culture of bCAF derived directly from human samples reduces their myofibroblastic characteristics. We herein show by single-cell RNA-sequencing analysis of bCAFs that MCL-1 knock down induces a phenotypic shift from wound-myCAF to IL-iCAF, characterized by the upregulation of genes associated with inflammation as well as angiogenesis-related genes. In vitro, genetic and pharmacologic MCL-1 inhibition increases VEGF secretion by bCAFs, enhancing endothelial cell tubulogenesis. In a chicken chorioallantoic membrane (CAM) model in ovo, co-engraftment of breast cancer cells and bCAFs with reduced MCL-1 expression leads to heightened peritumoral vascular density, driven by VEGF. Mechanistically, the pro-angiogenic phenotype revealed by MCL-1 inhibition is dependent on BAX-BAK activity. It results in NF-{kappa}B activation, inhibition of which by a IKK{beta} inhibitor suppresses the transcription of VEGF and pro-inflammatory factors triggered by MCL-1 inhibition in bCAFs. Chemotherapy induces a downregulation of MCL-1 in bCAFs and it promotes a pro-angiogenic phenotype, counteracted by overexpressed MCL-1. Overall, these findings uncover a novel regulatory function of MCL-1 in determining bCAF subpopulation differentiation and highlight its role in modulating their pro-angiogenic properties, in response to treatment in particular.

cancer biology↗